Replies to post #217781 on Anavex Life Sciences Corp (AVXL)

[Lima4918]

Hampel describes his work at Eisai, which is to Create “novel therapies” for “early stage of disease.”

He is NOT connecting himself to the failed, corrupt Aducanumab trial and that amyloid hypothesis.

He is going to “innovate.”

His word, “innovate”

[mrplmer]

Great Hair Style.